- Aditxt Inc (NASDAQ:ADTX) has announced data from Phase 3 PRESECO trial evaluating oral Avigan/Reeqonus (favipiravir) as a potential at-home therapy for mild-to-moderate COVID-19, run by Appili Therapeutics Inc.
- The trial did not achieve statistical significance on the primary endpoint of time to sustained clinical recovery. Additional analyses of the trial data are ongoing.
- Related Link: Aditxt Shares Surge On AiPharma Acquisition, Holder Of COVID-19 Candidate.
- The trial enrolled around 1,200 patients with mild-to-moderate COVID-19 from 38 U.S., Mexico, and Brazil study sites.
- "We are reviewing and evaluating the announced results and data and will be discussing them with AiPharma Global to determine the best course of action," stated Aditxt Co-Founder and CEO Amro Albanna.
- Price Action: ADTX shares are down 21.60% at $1.42 during the market session on the last check Friday.
Aditxt Acquisition-Partner's At-Home COVID-19 Drug Fails In Late-Stage Trial
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.